FDA Approval
5 articles on FDA Approval, written by Shotlee and medically reviewed for clinical accuracy.
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
4 min read
Querying 'weight' might display Ozempic in search outcomes. This is a pharmaceutical promotion gap
When individuals search for 'weight loss,' Ozempic often appears prominently despite lacking FDA approval for that purpose. This occurs through paid search advertisements that bypass traditional ad regulations. Experts urge consumers to seek independent sources for accurate health information.
3 min read
Should You Invest in Novo Nordisk, the Ozempic Manufacturer, in 2026?
Investing in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, has faced challenges recently, with shares declining. However, recent FDA approval of an oral form of Wegovy could change the company's trajectory. Analyzing competition and market dynamics is vital for investment decisions.
2 min read
Optum Rx: Why Payers Should Monitor These 3 Pipeline Medications
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
4 min read